Micro Solutions Life ScienceRU

Micro Solutions / Life Science

NGS panel BRCAaccuTest PLUS

NGS test of hereditary breast and ovarian cancer: BRCA1 and BRCA2 genes

Product overview

NGS test of hereditary breast and ovarian cancer: BRCA1 and BRCA2 genes

for blood samples and FFPE tissue, sequencing on the Illumina MiSeq platform

The BRCAaccuTest PLUS NGS test detects BRCA1 and BRCA2 gene mutations from blood and FFPE tissue samples, helping to assess the risk of hereditary breast and ovarian cancer.

The next-generation sequencing test system identifies pathogenic variants in BRCA1 and BRCA2 genes in genomic DNA from blood or tumor FFPE tissue samples. Sequencing is performed on Illumina MiSeq devices with an average coating of about 200× for germinal and 1,000× for somatic samples. NGeneAnalySys, which forms a clinical report.

The BRCAaccuTest PLUS panel covers the BRCA1 and BRCA2 genes. Diagnostic efficacy was confirmed in a sample of 108 samples - the results are more than 99% matched.

Key figures

2

BRCA1/BRCA2 gene

CE-IVD

certification

1 000×

somatication

>99%

diagnostic match

Applications

Models and configurations

precision

Clinical application

Platform

Panel

GenesBRCA1, BRCA2
Type of samplegenomic DNA from blood or FFPE tissue
Average coverage~200× (germinal samples); ~1,000× (somatic samples)
Clinical validation108 samples, diagnostic match over 99%

Platform and software

SequencingIllumina MiSeq
AnalysisNGeneAnalySys

Certification

StatusCE-IVD

Related equipment types

Related products

Classification

Documents

Manufacturer sources